. 2016 Sep 28;7(44):71703–71709. doi: 10.18632/oncotarget.12323

Table 4. Genetic polymorphisms and prognosis analysis.

SNP_ID	Alleles A^a/B	N	N of events	Median survival times (± SE)	Cumulative proportion of patients surviving after the indicated time (Estimate ± SE)			P^a	Crude HR (95.0% CI)	P^b	Adjusted HR (95.0% CI)
SNP_ID	Alleles A^a/B	N	N of events	Median survival times (± SE)	1 year	3 years	5years	P^a	Crude HR (95.0% CI)	P^b	Adjusted HR (95.0% CI)
rs1321311	G/G	117	65		0.89 ± 0.03	0.61 ± 0.05	0.52 ± 0.05
	T/G	53	35	62.00 ± 13.26	0.76 ± 0.06	0.49 ± 0.07	0.34 ± 0.08	0.027	1.60 (1.05~2.43)	0.022^*	1.64 (1.07~2.51)
	T/T	0
rs2494938	G/G	91	50	62.00 ± 14.65	0.82 ± 0.04	0.60 ± 0.05	0.52 ± 0.06	0.066		0.038
	A/G	58	36	44.00 ± 6.73	0.52 ± 0.06	0.59± 0.07	0.43 ± 0.07	0.663	1.10 (0.72~1.69)	0.952	1.01 (0.65~1.57)
	A/A	8	7	14.00 ± 4.24	0.63 ± 0.17	0.25 ± 0.15	0.25 ± 0.15	0.020	2.58 (1.16~5.72)	0.012^*	2.85 (1.26~6.46)
rs9363918	G/G	126	65	71.00 ± 13.39	0.86 ± 0.03	0.62 ± 0.04	0.53 ± 0.05	0.014		0.025
	T/G	41	34	35.00 ± 2.46	0.81 ± 0.06	0.43 ± 0.08	0.30 ± 0.07	0.006	1.80 (1.19~2.73)	0.009^*	1.78 (1.15~2.74)
	T/T	3	1			0.67 ± 0.27	0.67 ± 0.27	0.474	0.48 (0.07~3.55)	0.515	0.51 (0.07~3.83)
rs3016539	A/A	107	68	44.00	0.81 ± 0.04	0.54 ± 0.05	0.39 ± 0.05
	A/G	62	31	85.00	0.92 ± 0.04	0.64 ± 0.06	0.59 ± 0.06	0.015	0.59 (0.38~0.90)	0.027^*	0.60(0.39~0.94)
	G/G	0

Abbreviations: SNP, Single-nucleotide polymorphism; CI, confidence interval; HR, hazard ratio; Adjusted HR: adjusted by age, differentiation, clinical stage, and treatment.

p < 0.05.